



NeuroScientific
BIOPHARMACEUTICALS

Level 1, 45 Stirling Highway
Nedlands WA 6009 Australia

9 January 2019

ASX Market Announcements
Australian Securities Exchange
Exchange Centre
Level 4, 20 Bridge Street
Sydney NSW 2000

Electronic Lodgement

**NeuroScientific Biopharmaceuticals Limited ('Company')
Notice under ASX Listing Rule 3.10A**

Dear Sir / Madam

In accordance with ASX Listing Rule 3.10A, the Board of NeuroScientific Biopharmaceuticals Limited (ASX:NSB) advises that the following securities are due for release from mandatory escrow on 18 January 2019 to UTAS Holdings Pty Ltd:

Number of Securities	Type of Security	Release Date
746,269	Ordinary Fully Paid	18 January 2019

Please do not hesitate to contact me should you have any questions or queries.

Yours faithfully

Thomas Spencer
Company Secretary
+ 61 491 108 250

About Neuroscientific Biopharmaceuticals Limited

NeuroScientific Biopharmaceuticals (ASX:NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer's disease, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB. For more information, please visit www.neuroscientific.com